K2M Group Holdings Inc. (NASDAQ:KTWO) major shareholder Carson Anderson & Stow Welsh sold 4,416,825 shares of the stock in a transaction dated Wednesday, November 16th. The shares were sold at an average price of $18.39, for a total value of $81,225,411.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

K2M Group Holdings Inc. (NASDAQ:KTWO) opened at 18.84 on Tuesday. K2M Group Holdings Inc. has a 52-week low of $10.10 and a 52-week high of $21.67. The stock has a 50 day moving average price of $18.32 and a 200 day moving average price of $16.20. The stock’s market cap is $794.99 million.

K2M Group Holdings (NASDAQ:KTWO) last posted its earnings results on Wednesday, November 2nd. The medical device company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.11. K2M Group Holdings had a negative return on equity of 13.03% and a negative net margin of 16.45%. The business earned $59.30 million during the quarter, compared to the consensus estimate of $58.21 million. During the same period in the previous year, the business earned ($0.25) EPS. The business’s quarterly revenue was up 7.8% on a year-over-year basis. On average, equities research analysts forecast that K2M Group Holdings Inc. will post ($0.97) EPS for the current year.

Several research firms recently commented on KTWO. Zacks Investment Research raised K2M Group Holdings from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Tuesday, November 8th. RBC Capital Markets began coverage on K2M Group Holdings in a report on Monday, October 10th. They set an “outperform” rating and a $23.00 target price on the stock. Royal Bank Of Canada began coverage on K2M Group Holdings in a report on Monday, October 10th. They set an “outperform” rating and a $23.00 target price on the stock. Needham & Company LLC reaffirmed a “strong-buy” rating and set a $22.00 target price (up from $21.00) on shares of K2M Group Holdings in a report on Friday, August 5th. Finally, Gabelli began coverage on K2M Group Holdings in a report on Friday, September 16th. They set a “buy” rating and a $22.00 target price on the stock. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. K2M Group Holdings currently has a consensus rating of “Buy” and an average target price of $22.22.

A number of institutional investors have recently modified their holdings of the stock. Morgan Stanley boosted its position in shares of K2M Group Holdings by 293.9% in the third quarter. Morgan Stanley now owns 6,306 shares of the medical device company’s stock valued at $112,000 after buying an additional 4,705 shares during the period. BlackRock Group LTD boosted its position in shares of K2M Group Holdings by 4.3% in the third quarter. BlackRock Group LTD now owns 8,340 shares of the medical device company’s stock valued at $147,000 after buying an additional 342 shares during the period. BlackRock Advisors LLC boosted its position in shares of K2M Group Holdings by 31.4% in the second quarter. BlackRock Advisors LLC now owns 12,611 shares of the medical device company’s stock valued at $196,000 after buying an additional 3,016 shares during the period. Panagora Asset Management Inc. boosted its position in shares of K2M Group Holdings by 132.4% in the second quarter. Panagora Asset Management Inc. now owns 13,246 shares of the medical device company’s stock valued at $206,000 after buying an additional 7,547 shares during the period. Finally, 1st Global Advisors Inc. bought a new position in shares of K2M Group Holdings during the third quarter valued at about $223,000. Hedge funds and other institutional investors own 67.53% of the company’s stock.

K2M Group Holdings Company Profile

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions.

5 Day Chart for NASDAQ:KTWO

Receive News & Stock Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related stocks with our FREE daily email newsletter.